Home>Topics>Companies>Ranbaxy Laboratories

Ranbaxy Laboratories

  1. All
  2. Commentary
  3. Headlines
  1. UPDATE 2-India caps prices of 36 more drugs to improve access -govt official

    Headlines

    Fri, 19 Sep 2014

    * Local firms Cipla, Ranbaxy , Cadila among companies affected

  2. India's Ranbaxy says US authorities seek information on pricing data

    Headlines

    Wed, 17 Sep 2014

    MUMBAI, Sept 17 (Reuters) - Indian generic drugmaker Ranbaxy Laboratories Ltd said on Wednesday that federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement under the Medicaid program.

  3. Epirus Remicade biosimilar cleared in India

    Headlines

    Mon, 15 Sep 2014

    country. The company and commercialization partner Ranbaxy Laboratories expect to launch the product by Q1 2015 under the brand ..... agreement, Epirus will develop and supply BOW015 and Ranbaxy will register and commercialize BOW015 in India and

  4. Epirus, Ranbaxy win India approval for arthritis drug copy

    Headlines

    Mon, 15 Sep 2014

    Sept 15 (Reuters) - Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

  5. Gilead licenses Sovaldi to Indian firms

    Headlines

    Mon, 15 Sep 2014

    Indian companies are: Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories , Ltd ., Sequent Scientific Ltd., and Strides Arcolab Ltd. Under the terms of the agreements, the Indian firms

  6. Gilead licenses hepatitis C drug to Cipla, Ranbaxy , 5 others

    Headlines

    Mon, 15 Sep 2014

    NEW DELHI/MUMBAI, Sept 15 (Reuters) - U.S. drugmaker Gilead Sciences Inc said on Monday it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to...

  7. BRIEF-Gilead Sciences says licensed Hep C drug sovaldi to 7 companies

    Headlines

    Mon, 15 Sep 2014

    * Says licensed Hep C drug Sovaldi to 7 companies including Cipla Ltd, Mylan laboratories, Ranbaxy

  8. UPDATE 1-Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor

    Headlines

    Fri, 12 Sep 2014

    Sept 12 (Reuters - Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of a U.S. antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the best-selling cholesterol drug Lipitor.

  9. UPDATE 1-Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor

    Headlines

    Fri, 12 Sep 2014

    Sept 12 (Reuters) - Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of an antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the cholesterol drug Lipitor, the best-selling drug in history.

  10. BRIEF-Pfizer, Ranbaxy win dismissal of lawsuit by "direct purchaser" plaintiffs over generic Lipitor

    Headlines

    Fri, 12 Sep 2014

    Sept 12 (Reuters) - * U.S. judges grants Pfizer Inc Ranbaxy Laboratories Ltd

« Prev1234Next »
Content Partners